UPDATE: Living Cell faces slower road to commercialisation as trials get more analysis

UPDATE: Living Cell faces slower road to commercialisation as trials get more analysis
Rebecca Howard
(Updates to add share price reaction)  By Rebecca Howard Nov. 10 (BusinessDesk) - ASX-listed Kiwi biotech firm Living Cell Technologies' shares plunged 84 percent after the company said it won't immediately be seeking provisional consent for its treatment for Parkinson's disease when its latest trial did not show a "statistically significant difference" between people who received the treatment and a control group.  The Melbourne-based company halted trading of its shares yesterday ahead of the trial's results, which it was hoping woul...